Week 232 Dopamine (And Movement/Parkinsons Disease)
To link the neurobiology of dopamine to its roles in both health and disease states
- 1.The dopamine-producing region of the brain which dies in Parkinsons disease is called the
- A.
Amygdala
- B.
Basal nucleus of Meynert
- C.
Locus Coeruleus
- D.
Raphe Nucleus
- E.
Substantia Nigra
- F.
Medical malpractice
- G.
Depersonalization
- H.
The Hippocratic oath
- I.
Reverse psychology
- J.
A vicious circle
- 2.Dopamine regulates movement principally through projections from the substantia nigra to the
- A.
Dorsal Striatum
- B.
Globus Pallidus
- C.
Motor Cortex
- D.
Subthalamic Nucleus
- E.
Ventral Striatum
- 3.The striatum, globus pallidus, substantia nigra and subthalamic nucleus are all part of the
- A.
Basal Ganglia
- B.
Brainstem
- C.
Cranial nerves
- D.
Hypothalamus
- E.
Thalamus
- 4.The substantia nigra is so named, and clearly visible on brain sections, because it
- A.
Is black
- B.
Is located outside of the four major lobes and looks like a 'little brain'
- C.
Is shaped like a seahorse
- D.
Is the major white matter structure linking the two hemispheres
- E.
Is very highly folded
- 5.Dopamine is broken down by
- A.
Acetylcholinesterase
- B.
Cyclooxygenase
- C.
Dopa decarboxylase
- D.
Dopaminase
- E.
Monoamine oxidase
- 6.L-DOPA is converted into dopamine by
- A.
Acetylcholinesterase
- B.
Cyclooxygenase
- C.
Dopa decarboxylase
- D.
Dopaminase
- E.
Monoamine oxidase
- 7.Patients with Parkinsons disease suffer from a lack of dopamine
- A.
True
- B.
False
- 8.Carbidopa is a
- A.
Dopa decarboxylase inhibitor
- B.
Dopamine receptor agonist
- C.
Dopamine reuptake inhibitor
- D.
Monoamine oxidase inhibitor
- E.
Stimulator of dopamine release
- 9.A dopa decaroxylase inhibitor (such as Carbidopa), which inhibits the conversion of L-DOPA into dopamine, should not be given to patients with Parkinsons disease
- A.
True
- B.
False
- 10.Selegiline is a
- A.
Dopa decarboxylase inhibitor
- B.
Dopamine receptor agonist
- C.
Dopamine reuptake inhibitor
- D.
Monoamine oxidase inhibitor
- E.
Stimulator of dopamine release
- 11.Entacapone is a
- A.
Dopa decarboxylase agonist
- B.
Catechol-O-methyl transferase inhibitor
- C.
Dopamine receptor antagonist
- D.
Monoamine oxidase agonist
- E.
Stimulator of dopamine breakdown
- F.
Cruelty
- G.
Assiduity
- H.
Determination
- I.
Delusions of grandeur
- J.
Work ethic
- 12.Ropinirole is a
- A.
Dopa decarboxylase inhibitor
- B.
Dopamine receptor agonist
- C.
Dopamine reuptake inhibitor
- D.
Monoamine oxidase inhibitor
- E.
Stimulator of dopamine release
- 13.Pramipexole is a
- A.
Dopa decarboxylase inhibitor
- B.
Dopamine receptor agonist
- C.
Dopamine reuptake inhibitor
- D.
Monoamine oxidase inhibitor
- E.
Stimulator of dopamine release
- 14.Possible side effects of dopamine agonists such as ropinirole and prampipexole include (tick all that apply)
- A.
Constipation
- B.
Hallucinations
- C.
Hypersexuality
- D.
Nausea
- E.
Pathological gambling
- 15.Metoclopramide is primarily used as an
- A.
Anticoagulant
- B.
Antidepressant
- C.
Antiemetic
- D.
Antihistamine
- E.
Antipsychotic
- 16.Haloperidol is primarily used as an
- A.
Anticoagulant
- B.
Antidepressant
- C.
Antiemetic
- D.
Antihistamine
- E.
Antipsychotic
- F.
A spiritual awakening
- G.
Crippling remorse
- H.
Mixed emotions
- I.
False dilemm
- J.
Homesickness
- 17.The use of haloperidol and metoclopramide in Parkinsons disease is potentially problematic because they
- A.
Block dopamine receptors
- B.
Block dopamine reuptake
- C.
Block dopamine synthesis
- D.
Stimulate dopamine receptors
- E.
Stimulate dopamine breakdown
- 18.The clinical potency of 'typical' antipsychotics shows good correlation with their ability to
- A.
Block dopamine release
- B.
Block dopamine D1 receptors
- C.
Block dopamine D2 receptors
- D.
Stimulate dopamine breakdown
- E.
Stimulate dopamine reuptake
- 19.Dyskinesia is best described as
- A.
Awareness of position and movement
- B.
Excessive, abnormal, random fidgety movements
- C.
Rhythmic oscillatory movement
- D.
Slow or sustained abnormal movement of limb
- E.
Stereotyped brief movement
- 20.Dopamine hydrochloride administered via the intravenous route does not cross the blood-brain barrier
- A.
True
- B.
False
Questions: 10 | Attempts: 1909 | Last updated: Mar 21, 2022
-
Sample QuestionWhat was Parkinson's Disease originally refered to?
Questions: 28 | Attempts: 120344 | Last updated: Mar 22, 2022
-
Sample QuestionYou are having lunch with a friend in your office cafeteria. It is seemingly quiet, and the only other sound is the soft humming of the refrigerator. Your friend sits across from you and places her container on the table. You take a quick peek; which of the following foods listed would alarm you the most?
Questions: 10 | Attempts: 34914 | Last updated: Mar 22, 2022
-
Sample QuestionLet's get the ball rolling! Do you regularly suffer from stomach cramps?
Back to top